Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Protalix BioTherapeutics, Inc.'s quarterly P/E stands at 18.5x, up 144.5% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 391.2% YoY to 17.4x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 78.69 | 18.50 | 185.00 | — | 5.49 | 7.57 | — | — | — | — | 2.38 | — | — |
| — | +144.5% | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.09 | 2.51 | 1.92 | 4.85 | 2.09 | 1.15 | 1.59 | 6.14 | 3.10 | 3.36 | 1.19 | 3.15 | 2.04 |
| — | +117.9% | +20.7% | -21.0% | -32.5% | -65.7% | +34.2% | +95.0% | +51.7% | +269.9% | -19.5% | +316.7% | +84.2% | |
| P/B Ratio | 5.40 | 3.39 | 2.41 | 4.34 | 3.53 | 2.55 | 3.00 | 3.09 | 3.87 | 3.64 | 4.27 | 119.75 | — |
| — | +32.8% | -19.7% | +40.4% | -8.8% | -29.8% | -29.7% | -97.4% | — | — | — | — | — | |
| P/FCF | 29.55 | — | — | — | 10.68 | 5.15 | — | 6.41 | 9.71 | — | 8.72 | — | — |
| — | — | — | — | +10.1% | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 39.11 | 17.37 | 17.58 | — | 4.58 | 3.54 | — | — | — | — | 1.74 | — | — |
| — | +391.2% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 52.14 | 17.98 | 18.65 | — | 4.72 | 3.69 | — | — | — | — | 1.72 | — | — |
| — | +387.3% | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Protalix BioTherapeutics, Inc.'s operating margin was 11.9% in Q3 2025, up 4.5 pp QoQ and down 10.3 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 4.5% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.5% | 53.4% | 62.5% | 19.1% | 78.7% | 53.4% | 29.8% | 30.6% | 15.5% | 52.7% | 82.5% | 67.8% | 72.2% |
| — | +0.0% | +109.6% | -37.5% | +406.1% | +1.3% | -63.8% | -54.9% | -78.5% | +5.1% | +54.7% | +8.5% | +14.3% | |
| Operating Margin | 7.3% | 11.9% | 7.5% | -41.0% | 39.6% | 22.2% | -18.0% | -129.6% | -53.5% | -18.2% | 58.2% | -25.6% | -29.0% |
| — | -46.3% | +141.6% | +68.4% | +173.9% | +221.8% | -130.9% | -405.2% | -84.9% | +17.2% | +192.3% | -120.6% | +56.6% | |
| Net Margin | 5.5% | 13.2% | 1.0% | -35.8% | 35.6% | 18.0% | -16.4% | -122.6% | -57.6% | -17.9% | 55.1% | -32.7% | -43.4% |
| — | -26.8% | +106.4% | +70.8% | +161.8% | +200.7% | -129.7% | -275.4% | -32.8% | +28.8% | +190.5% | -129.8% | +44.3% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 7.6% | 4.6% | 0.3% | -8.2% | 17.2% | 10.6% | -7.5% | -14.5% | -16.8% | -4.8% | 96.7% | -310.6% | — |
| — | -56.8% | +104.6% | +43.6% | +202.0% | +321.2% | -107.8% | +95.3% | — | — | — | — | — | |
| ROA | 3.7% | 2.9% | 0.2% | -4.9% | 9.6% | 4.2% | -2.4% | -5.3% | -7.0% | -2.1% | 25.0% | -5.1% | -6.6% |
| — | -30.7% | +108.9% | +6.8% | +236.9% | +300.8% | -109.7% | -3.0% | -5.7% | +65.4% | +401.9% | -59.0% | +21.6% | |
| ROIC | 8.8% | 3.8% | 2.6% | -10.4% | 27.2% | 13.8% | -5.9% | -11.2% | -10.5% | -4.7% | 167.1% | -50.8% | -22.5% |
| — | -72.6% | +143.6% | +7.2% | +359.0% | +394.8% | -103.5% | +78.0% | +53.3% | +78.6% | +496.4% | — | +61.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Protalix BioTherapeutics, Inc.'s Debt/EBITDA ratio is 3.3x, down from 3.5x last quarter — at a moderate level that warrants monitoring. The current ratio has improved 53.4% YoY to 3.03x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.15 | 0.11 | 0.12 | 0.13 | 0.18 | 0.97 | 0.89 | 0.78 | 0.68 | 0.67 | 33.30 | — |
| — | -11.8% | -88.9% | -86.9% | -83.7% | -74.2% | +45.0% | -97.3% | — | — | — | — | — | |
| Debt / EBITDA | 1.06 | 3.27 | 3.49 | — | 0.73 | 1.32 | — | — | — | — | 1.25 | — | — |
| — | +148.3% | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.34 | 3.03 | 2.72 | 2.49 | 2.34 | 1.98 | 1.33 | 1.38 | 1.54 | 1.67 | 3.18 | 1.76 | 1.38 |
| — | +53.4% | +103.7% | +80.9% | +52.7% | +18.0% | -58.1% | -21.8% | +11.0% | +25.5% | +98.3% | +9.8% | -25.5% | |
| Quick Ratio | 1.52 | 2.06 | 1.84 | 1.69 | 1.52 | 1.27 | 0.98 | 0.97 | 1.12 | 1.18 | 2.33 | 1.11 | 0.87 |
| — | +62.9% | +88.4% | +74.2% | +35.6% | +7.5% | -58.1% | -13.1% | +29.1% | +29.4% | +117.7% | -1.5% | -34.3% | |
| Interest Coverage | 3.69 | 11.84 | 1.50 | -690.83 | 1201.50 | 13.35 | -6.61 | -12.45 | -7.25 | -4.10 | 15.65 | -3.79 | -3.49 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonProtalix BioTherapeutics, Inc.'s current P/E is 78.7x. The average P/E over the last 3 quarters is 69.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Protalix BioTherapeutics, Inc.'s current operating margin is 7.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Protalix BioTherapeutics, Inc.'s business trajectory between earnings reports.